When I started this clinic in 2020, my goal was to practice medicine differently: to treat weight as the chronic medical condition that it is, and to offer care grounded in evidence, realism and compassion.
Every year since, the science has moved faster, and it keeps reshaping what we can offer through our metabolic program. We are living in an unusually important moment in weight medicine.
Is there a GLP-1 pill for weight loss now?
Yes. The FDA approved oral semaglutide 25 mg daily for chronic weight management, the first GLP-1 pill approved specifically for obesity. In the pivotal phase 3 trial published in the New England Journal of Medicine, participants lost an average of 13.6 percent of body weight over 64 weeks, against 2.2 percent with placebo.
That is meaningful weight loss over just over a year. For many patients the significance is not only the magnitude but the route. A pill lowers barriers for people hesitant about injections or access.
As with injectable GLP-1 therapies, gastrointestinal symptoms were common, particularly during dose escalation. About 74 percent of participants experienced GI effects, most commonly nausea and vomiting, compared with 42 percent on placebo.
That underscores the importance of careful titration and medical supervision rather than rushing dosing.
What else is coming?
What excites me is not one approval but the depth of the pipeline. Three candidates stand out: orforglipron, an oral small-molecule GLP-1 agonist; CagriSema, which pairs semaglutide with an amylin analog; and retatrutide, a triple agonist. Each works differently, and each is at a different stage.
In its phase 2 trial over 72 weeks, orforglipron produced average weight loss ranging from roughly 7.5 percent at the lowest dose to about 11.2 percent at 36 mg, against roughly 2.1 percent with placebo.
GI side effects were most common during early dose escalation. Longer-term phase 3 data will matter, but this is a promising oral option that could expand access.
CagriSema combines semaglutide with cagrilintide, which targets appetite regulation through a different pathway. In its phase 3 trial over 68 weeks, average weight loss was about 20.4 percent on a conservative analysis and 22.7 percent among those who adhered closely, against roughly 3 percent with placebo.
GI side effects were common, as expected with combination therapy, but discontinuation due to adverse events was relatively low at around 6 percent given the magnitude of weight loss.
Retatrutide targets GLP-1, GIP and glucagon receptors. In phase 2 over 48 weeks, the highest doses reached roughly 22 to 24 percent of body weight, nearly double what we considered extraordinary a few years ago.
These are early data. Longer trials are still needed to understand durability, safety and tolerability, and discontinuation rates were higher at higher doses.
Does any of this change what good care looks like?
No. No medication is a cure, and no trial captures real life perfectly. Careful prescribing, thoughtful titration, long-term safety over shortcuts, and compassion over shame do not go out of date because the molecules improved.
But taken together, these data tell an important story. Weight is being treated seriously. Mechanisms are improving. Options are expanding. Personalization is becoming possible.
The broader medical system is catching up to what many of us have known all along. This is a disease, full stop, and people deserve effective, evidence-based care.
